Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28232944 | 0.84 | TSHR (0.56) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL4621117 | 0.84 | TSHR (0.56) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL12408480 | 0.81 | TSHR (0.52) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL3590339 | 0.80 | TSHR (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL13535468 | 0.78 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL28499564 | 0.75 | MAOB (0.43) | TSHRKMT2AMAOBSLC1A1CYP1A2 | |
| SCHEMBL28499565 | 0.75 | MAOB (0.43) | TSHRKMT2AMAOBSLC1A1CYP1A2 | |
| SCHEMBL16732414 | 0.75 | KMT2A (0.55) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL21540243 | 0.75 | KMT2A (0.55) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL31059752 | 0.75 | MAOB (0.43) | TSHRKMT2AMAOBSLC1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2844658-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | GENENTECH INC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-9212186-B2 | Bicyclic pyrazole LRRK2 small molecule inhibitors | GENENTECH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| EP-2844658-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2015-03-11 | — | — | EP | disclosed |
| US-20150051201-A1 | BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS | GENENTECH, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| WO-2013164323-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051201-A1 | BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS | LRRK2, PARK7, PINK1 | TSHR 1111/4885CA1 4794/4885CA2 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.